The aim of our study is to confirm the utility of warm compresses (WC) and artificial tears (AT) in meibomian gland dysfunction (MGD) management and to understand if its association with topical cyclosporine A (CsA) improves outcomes.
Methods
Patients with diagnosis of MGD-related dry eye were evaluated. In this prospective, randomized, double-masked study, patients were randomized in two treatments: AT plus WC (group A), and AT plus WC plus CsA 0.05% ophthalmic emulsion (group B). At baseline and at 1, 3, and 6 months, Ocular Surface Disease Index (OSDI) questionnaire was completed, and tear evaluation (BUT, Schirmer and osmolarity test), ocular surface evaluation (fluorescein and lissamine green staining), clinical (Shimazaki grading) and in vivo confocal microscopy (IVCM) evaluation of rete ridges (RRs) were performed.
Results
A total of 40 eyes, 20 in each group, completed the study. Analysis of OSDI, tear test, ocular surface evaluation and clinical grading of MG showed significant improvement at 6 months, whereas no difference was found between the two groups at 6 months. The analysis of IVCM showed significant improvement in both groups, but significantly better results in group B were found compared to group A at 6 months.
Conclusion
WC performed 3 times daily during the 1st month and once daily afterwards, in addition to AT, were useful to manage the obstruction of MG and related signs and symptoms. Additional effects of CsA were visible in IVCM only at 6 months. IVCM is an effective tool to monitor treatments in MGD.
NicholsKK, et al.The international workshop on meibomian gland dysfunction: Executive summary. Investig Ophthalmol Vis Sci2011;52(4):1922-1929. doi:10.1167/iovs.10-6997a
TomlinsonA, et al.The international workshop on meibomian gland dysfunction: Report of the diagnosis subcommittee. Investig Ophthalmol Vis Sci2011;52(4): 2006-2049. doi:10.1167/iovs.10-6997f
4.
ThengJZhouLTanD,et al.Distribution of cyclosporin A in the cornea after topical or oral administration. J Ocul Pharmacol Ther2002;18(1): 83-88. doi:10.1089/108076802317233243
5.
WilsonSEPerryHD. Long-term Resolution of Chronic Dry Eye Symptoms and Signs after Topical Cyclosporine Treatment. Ophthalmology2007;114(1):76-79. doi:10.1016/j.ophtha.2006.05.077
6.
TokerEAsfuroǧluE. Corneal and conjunctival sensitivity in patients with dry eye: The effect of topical cyclosporine therapy. Cornea2010;29(2):133-1340. doi:10.1097/ICO.0b013e3181acf68d
7.
KaraNAltinkaynakHGokerY,et al.Evaluation of corneal morphologic and functional parameters after use of topical cyclosporine-A 0.05% in dry eye. J Ocul Pharmacol Ther2012;28(6):593-597. doi:10.1089/jop.2012.0096
8.
SullivanBD, et al.Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: Clinical implications. Acta Ophthalmol2014;92(2): 161-166. doi:10.1111/aos.12012
9.
BronAJEvansVESmithJA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea2003;22(7):640-650. doi:10.1097/00003226-200310000-00008
10.
ShimazakiJSakataMTsubotaK. Ocular Surface Changes and Discomfort in Patients With Meibomian Gland Dysfunction. Arch Ophthalmol1995;113(10):1266-1270. doi:10.1001/archopht.1995.01100100054027
11.
RandonM, et al.A new classification for meibomian gland diseases with in vivo confocal microscopy. J Fr Ophtalmol2016;39(3):239-247. doi:10.1016/j.jfo.2015.07.015
12.
ZhouSRobertsonDM. Wide-field in vivo confocal microscopy of meibomian gland acini and rete ridges in the eyelid margin. Investig Ophthalmol Vis Sci2018;59(19):4249-4257. doi:10.1167/iovs.18-24497
13.
MatsumotoYSatoEAIbrahimOMA,et al.The application of in vivo laser confocal microscopy to the diagnosis and evaluation of meibomian gland dysfunction. Mol Vis2008;14:1263-1271.
14.
VillaniE, et al.In vivo confocal microscopy of meibomian glands in contact lens wearers. Investig Ophthalmol Vis Sci2011;52(8):5215-5219. doi:10.1167/iovs.11-7427
15.
IbrahimOMA, et al.In vivo confocal microscopy evaluation of meibomian gland dysfunction in atopic-keratoconjunctivitis patients. Ophthalmology2012;119(10):1961-1968. doi:10.1016/j.ophtha.2012.04.001
16.
MastropasquaL, et al.In vivo laser scanning confocal microscopy of the ocular surface in glaucoma. Microsc Microanal2014;20(3):879-894. doi:10.1017/S1431927614000324
17.
LiM, et al.Rete ridges in eyelid margin and inflammatory cytokines in meibomian gland dysfunction associated with dry eye symptom. Curr Eye Res2020;46(2):202-209. doi:10.1080/02713683.2020.1788102
18.
BaudouinC, et al.Revisiting the vicious circle of dry eye disease: A focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol2016;100(3):300-306. doi:10.1136/bjophthalmol-2015-307415
19.
GeerlingG, et al.The international workshop on meibomian gland dysfunction: Report of the subcommittee on management and treatment of meibomian gland dysfunction. Investig Ophthalmol Vis Sci2011;52(4):2050-2064. doi:10.1167/iovs.10-6997g
20.
LindsleyKMatsumuraSHatefE,et al.Interventions for chronic blepharitis. Cochrane Database Syst Rev2012. doi:10.1002/14651858.cd005556.pub2
21.
AkpekEK, et al.Dry Eye Syndrome Preferred Practice Pattern®. Ophthalmology2019;126(1):286-334. doi:10.1016/j.ophtha.2018.10.023
22.
IaccheriB, et al.Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine. Eye2017;31(5):788-794. doi:10.1038/eye.2017.3
23.
PerryHD, et al.Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea2006;25(2):171-175. doi:10.1097/01.ico.0000176611.88579.0a
24.
RubinMRaoSN. Efficacy of topical cyclosporin 0.05% in the treatment of posterior blepharitis. J Ocul Pharmacol Ther2006;22(1):47-53. doi:10.1089/jop.2006.22.47
25.
KunertKSTisdaleASSternME,et al.Analysis of topical cyclosporine treatment of patients with dry eye syndrome: Effect on conjunctival lymphocytes. Arch Ophthalmol2000;118(11):1489-1496. doi:10.1001/archopht.118.11.1489
26.
KilmartinDJForresterJVDickAD. Cyclosporin A therapy in refractory non-infectious childhood uveitis. Br J Ophthalmol1998;82(7):737-742. doi:10.1136/bjo.82.7.737
27.
KimHY, et al.Clinical efficacy of combined topical 0.05% cyclosporine a and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction. Int J Ophthalmol2018;11(4):593-600. doi:10.18240/ijo.2018.04.09
28.
PflugfelderSC, et al.Management and therapy of dry eye disease: Report of the management and therapy subcommittee of the international Dry Eye WorkShop (2007). Ocul Surf2007;5(2):163-178. doi:10.1016/s1542-0124(12)70085-x
29.
SchaumbergDA, et al.The international workshop on meibomian gland dysfunction: Report of the subcommittee on the epidemiology of, and associated risk factors for, MGD. Investig Ophthalmol Vis Sci2011;52(4):1994-2005. doi:10.1167/iovs.10-6997e
30.
BunyaVY, et al.Variability of tear osmolarity in patients with dry eye. JAMA Ophthalmol2015;133(6):662-667. doi:10.1001/jamaophthalmol.2015.0429
31.
PotvinRMakariSRapuanoCJ. Tear film osmolarity and dry eye disease: A review of the literature. Clin Ophthalmol2015;9:2039-2047. doi:10.2147/OPTH.S95242
32.
ThulasiPDjalilianAR. Update in Current Diagnostics and Therapeutics of Dry Eye Disease. Ophthalmology2017;124(11):27-33. doi:10.1016/j.ophtha.2017.07.022
RandonM, et al.In vivo confocal microscopy classification in the diagnosis of meibomian gland dysfunction. Eye2019;33(5):754-760. doi:10.1038/s41433-018-0307-9
35.
MatsumotoY, et al.The evaluation of the treatment response in obstructive meibomian gland disease by in vivo laser confocal microscopy. Graefe’s Arch Clin Exp Ophthalmol2009;247(6):821-829. doi:10.1007/s00417-008-1017-y
36.
Enríquez-de-SalamancaA, et al.Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis2010;16:862-873.
37.
LeeH, et al.Effects of topical loteprednol etabonate on tear cytokines and clinical outcomes in moderate and severe meibomian gland dysfunction: Randomized clinical trial. Am J Ophthalmol2014;158(6):1172-1183. doi:10.1016/j.ajo.2014.08.015
38.
YinYGongL. Reversibility of Gland Dropout and Significance of Eyelid Hygiene Treatment in Meibomian Gland Dysfunction. Cornea2017. doi:10.1097/ICO.0000000000001042
39.
DartJSmithG. External Eye Disease. Moorfields Man Ophthalmol2014;36(3):332-337. doi:10.5005/jp/books/12312_4.
40.
BlackieCASolomonJDGreinerJV,et al.Inner eyelid surface temperature as a function of warm compress methodology. Optom Vis Sci2008;85(8):675-683. doi:10.1097/OPX.0b013e318181adef
